Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Biliary decompression and stenting principles

Essential points for quick revision.

Saved on this device
!
Infected obstruction requires source control

Antibiotics cannot sterilise a pressurised obstructed biliary tree reliably; shock, confusion, oliguria or rising lactate with cholangitis demands urgent decompression as well as resuscitation.

Action: Stabilise airway and circulation, obtain blood cultures and begin an appropriate intravenous biliary antimicrobial, then coordinate the fastest safe ERCP, percutaneous or specialist EUS-guided route that will drain the infected segments.

Synopsis

Decide when biliary decompression is necessary, choose an anatomically appropriate route and removable or durable device, prevent ERCP harm, and verify that the intended liver volume drains.

  • Drain bile for cholangitis and for selected severe symptomatic obstruction, treatment delay or neoadjuvant therapy; do not equate jaundice alone with an automatic preoperative stent.
  • For stable suspected pancreatic cancer with obstructive jaundice, obtain pancreatic-protocol CT before drainage and usually proceed directly to resection when promptly operable.
  • ERCP is generally suited to distal obstruction; percutaneous access can target separated proximal sectors, and specialist EUS-guided drainage is an option after failed ERCP where expertise exists.

Key red flags

Do not fill a hilar duct with contrast unless it can be drained; an opacified isolated sector can become infected.

A recurrent fever, jaundice or pain after stenting indicates possible occlusion or migration and requires same-day clinical reassessment.

An uncovered metal stent should not be deployed across extrahepatic obstruction of unconfirmed cause because it cannot readily be removed.

Failed device

Recurrent jaundice, fever, rigors, pale stools or pain after initial improvement suggests occlusion, migration or tumour progression.

Reasoning priorities

01
Cross-sectional staging imaging

Define cause, obstruction level, vascular relationships and metastases before elective drainage.

Use pancreatic-protocol CT for suspected pancreatic cancer and MRI/MRCP for proximal duct mapping; intervention before imaging may obscure or infect the system.

Worked reasoning

Worked case: choose and verify distal drainageMatch the device to indication and diagnosis

A 74-year-old with biopsy-confirmed unresectable distal cholangiocarcinoma has bilirubin 248 micromol/L, disabling itch, no fever and an accessible papilla; CT shows no hilar separation.

  1. Confirm the palliative need for durable drainage. Assessment shows preserved renal function, satisfactory coagulation, no anticoagulant use and no NSAID contraindication, including proctitis, peptic bleeding, hypersensitivity or relevant cardiovascular disease such as NYHA II–IV heart failure. Anticipated complete drainage, no severe immunocompromise and no cholangioscopy mean routine antibiotic prophylaxis is not indicated in this afebrile case.
  2. Give diclofenac 100 mg rectally immediately before ERCP after those checks; obtain any required sampling and deploy a fully covered SEMS across the biopsy-confirmed distal CCA. Document its position and effective bile drainage.
  3. Within 48 hours urine is lighter, itch has improved and bilirubin falls to 181 micromol/L; there is no new abdominal pain, vomiting, fever or additional admission need for pancreatitis. PEP requires the clinical syndrome with new/worsened pain, pancreatic enzymes at least three times the upper limit at more than 24 hours, and admission or prolongation of admission; an isolated lipase rise is not the diagnosis.
  4. At oncology review bilirubin has fallen to 54 micromol/L; document stent model and position, give a 24-hour blockage contact and verify that systemic treatment can begin.

Key medicines

Rectal diclofenac for post-ERCP pancreatitis preventionESGE-supported off-label ERCP prophylaxis is diclofenac 100 mg as a single rectal suppository immediately before ERCP in an eligible adult; ERCP prevention is outside this product’s licensed indications. This is one dose, not a post-procedure course. Count all diclofenac exposure against the product maximum of 150 mg in 24 hours and avoid another systemic NSAID.Do not use with NSAID-triggered asthma, angioedema, urticaria or rhinitis, product hypersensitivity, active/recurrent peptic ulcer or GI bleeding, previous NSAID-related GI bleeding/perforation, proctitis, established heart failure NYHA II–IV, ischaemic heart disease, peripheral arterial or cerebrovascular disease, or severe renal/hepatic failure. Avoid concomitant systemic NSAIDs; assess anticoagulation, bowel inflammation, dehydration and renal perfusion. Diclofenac is contraindicated in the third trimester. Earlier pregnancy requires a clearly necessary indication with the lowest dose/shortest exposure: from week 20 fetal renal dysfunction/oligohydramnios and ductus arteriosus constriction can occur; several days of exposure warrant consideration of antenatal monitoring and discontinuation if these develop.
Open full textbook Answer 2 questions
Sources and review status5 sources · checked 8 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 8 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom